• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    MeiraGTx Holdings (MGTX) Has Rallied Sharply, Is The Current P/E Too Expensive?

    Simply Wall St·09/04/2026 07:33:17
    語音播報

    Recent Performance Snapshot for MeiraGTx Holdings

    With no single headline event setting the tone, MeiraGTx Holdings (MGTX) has drawn attention through its recent trading performance. The stock last closed at US$13.97, with mixed short term returns but stronger multi period gains.

    Over the past week the share price declined 1.2%. That contrasts with a gain of 13.7% over the past month and a rise of 55.2% in the past 3 months. Year to date the stock is up 78.9%, while the past year total return is 80.9%.

    Looking further back, the 3 year total return is approximately 15x, while the 5 year total return stands at 15.5%. These figures help frame how current prices relate to the stock’s longer track record for anyone reassessing exposure.

    For MeiraGTx Holdings, the recent 1-week share price softness contrasts with strong upward momentum over the past quarter and year to date, while the 1-year and 3-year total shareholder returns indicate that longer term holders have seen materially stronger outcomes.

    Scan beyond MeiraGTx Holdings and explore other high-momentum genetic medicine and biotech opportunities with the hand picked 21 high quality undiscovered gems that may still be flying under most radars.

    After such a steep multi period climb for MeiraGTx Holdings, some investors will wonder whether most of the easy money is already behind the stock or whether current fundamentals still leave room for further upside.

    Preferred Price-to-Earnings of 17x for MeiraGTx Holdings: Is it justified?

    The current P/E of 17x at MeiraGTx Holdings lines up closely with the wider US biotech sector and sits below the broader US market average. This points to a valuation that does not look stretched relative to many peers.

    The P/E ratio compares the company’s share price to its earnings per share and is a common reference point for profitable biotechs like MeiraGTx Holdings. For a business that has only recently moved into profitability, this metric helps you see how much investors are paying for each dollar of current earnings rather than for hoped for future profits alone.

    MeiraGTx Holdings is described as having become profitable over the past few years, with earnings growth figures that are difficult to interpret because of that recent transition. Earnings are forecast to decline by an average of 11.2% per year over the next 3 years. In that context, a P/E of 17x compared with an estimated fair P/E of 11.9x suggests the market is putting a relatively rich tag on those current earnings. The fair ratio hints at a level the valuation could move closer to if sentiment cools.

    Compared with the US biotechs industry average P/E of 17.1x, MeiraGTx Holdings trades almost in line with the sector. This implies the stock is being treated more like a typical biotech than a clear outlier despite the forecast decline in earnings. When stacked against a peer average P/E of 31.2x, however, the stock trades at a steep discount, which signals that investors as a group are less willing to pay up for MeiraGTx Holdings than for many similar sized companies.

    Explore the SWS fair ratio for MeiraGTx Holdings

    Result: Price-to-Earnings of 17x (OVERVALUED)

    However, you still need to weigh risks such as the forecast earnings decline of 11.2% a year, as well as ongoing clinical trial uncertainty across MeiraGTx Holdings' early stage pipeline.

    Find out about the key risks to this MeiraGTx Holdings narrative.

    Next Steps

    With sentiment on MeiraGTx Holdings split between concern about risks and interest in potential rewards, it helps to look at the full picture for yourself. If you want to see a concise summary of both sides of the argument, take a closer look at the 2 key rewards and 3 important warning signs

    Looking for more investment ideas beyond MeiraGTx Holdings?

    If you stop at MeiraGTx Holdings, you risk missing other opportunities that might fit your goals even better. Use the Simply Wall Street Screener to compare fresh ideas side by side.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.